ICP 022

Drug Profile

ICP 022

Alternative Names: ICP-022

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InnoCare Pharma
  • Class Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Phase I/II Mantle-cell lymphoma
  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Jun 2018 ICP 022 is available for licensing in World as of 13 Jun 2018 (InnoCare pipeline, June 2018)
  • 06 Jun 2018 InnoCare Pharma completes a phase I trial in Rheumatoid arthritis (In volunteers) in Australia (PO)
  • 16 Apr 2018 Phase-II clinical trials in Chronic lymphocytic leukaemia (Refractory metastatic disease) in China (PO) (InnoCare pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top